Accord is committed to putting user safety at the heart of our offering. Accord is a dynamic young company unencumbered by past practice and with an appetite for refreshing the way in which safe and efficacious pharmaceuticals are delivered to users, adding innovative features to our concepts and products.

2D Barcode: Data Matrix is a relatively recent 2- dimensional barcode development. This code has a high data capacity, variable sizing capabilities and ability to withstand harsh environments. It is most commonly used for product identification and lot tracking of pharmaceuticals. Several organisations have recommended the use of Data Matrix due to the advantages it offers:

• Improved data accuracy
• Faster data input and handling
• Cost benefit
• Flexibility

Unlike other companies in the sector, Accord is able to bring this advantageous product labelling to the market thanks to its high technology offering at our manufacturing facilities and product packing sites.

PharmaShield® is a system consisting of a superficial plastic sheathing around the vial, going from the reinforced non- PVC base to the vial seal.

Key Benefits:

• Protects from breakage and spillage
• Protects users from external vial contamination
• Protects essential product label information
• The use of non-PVC materials protects the environment
• Latex free – protects users with sensitivity
• Reinforced non-PVC base: provides greater stability during manipulation and further reduces risk of breakage if vial is dropped

Key benefits of vial seal:

• No risk of sharp edges which could potentially damage user
• Minimises potential disruption to crimp as FOC is removed
• Easy removal of FOC

Other Accord product features

• Barcode on label: to enhance stock control and reduce potential errors when dispensing the drug
• Flip-off cap
• Easy removal of FOC

By recognising that our infrastructure must always be appropriate to solving the problem at hand, we have taken a novel approach to our supply of medicines in the fragmented European market. The EU is the world´s biggest trading block encompassing over 550 million people, 27 countries and over 20% of world´s GDP. Whilst each market is very different, over the last decade the regulatory procedures required to gain approval to sell pharmaceuticals in the region have been harmonised.

The typical supply lead time from API order to provision of final goods can take over 6 months. Given the many supply shortages which currently exist in the region it is common for demand to fluctuate on a regular basis. It is difficult to adapt to this using a ´make to order´ supply scheme. Instead using a dedicated facility at Haverhill, Cambridgeshire, UK, Accord employs a state of the art ´pack to order´ or postponement strategy.

Simply put we produce large batches of common pharmaceutical product at our EMA and FDA approved facilities and then transfer as nude or undifferentiated products to the packing site. This bulk product is then held ready to pack upon requirement able to go to any of the 27 markets.

By employing this scheme we can shorten lead-times to a matter of weeks. This use of infrastructure is far more suitable to the volatile demand environment of the European trading block than conventional supply chains, all part of our i-4 concept.

Accord’s corporate social responsibility goes beyond our contribution to the environment through the application of regulations that favours its sustainability. Our contribution is directed to the community and specifically to healthcare professionals and patients.

Representative patient support initiatives are book publication of Claudia, One Year of My Life and Kit Appunti di un Viaggio®.

Both initiatives have had the cancer patient as the central actor bringing benefit to patient as well as family while accompanying the patient through a “Journey” while experiencing secondary effects of chemotherapy and radiotherapy. Kit Appunti di un Viaggio® has been recognised by different oncology associations and even by the Italian Ministry of Health.

Rather than simply imitating what has gone before we try to take a more inventive approach to product development. As an example we have reformulated Gemcitabine into a highly concentrated form. Whilst several other companies realised that users would prefer a solution versus the original powder product, they took the approach of making the concentration of the solution match that in the SmPC of the original product.

Instead we stepped back and realised that this approach meant a greater quantity of excipients being given to patients, a greater workload on aseptic pharmacy, greater storage requirements and a greater burden to the environment by having to dispose of more material per patient.

Accord developed the 100 mg/ml Gemcitabine solution. This is unique and offers the following advantages over other solution products:

• Easier to calculate dosing schedules reducing the chance of dosing errors
• Less time to withdraw the required dose reducing the burden on aseptic pharmacy
• Four presentation sizes designed to minimise wastage resulting in financial savings
• Smaller vials resulting in less use of precious storage space and ultimately reducing the material required to be incinerated
• An important environmental improvement
• Less inactive ingredients being given to patient

Accord’s environmental contribution starts in-house and also incorporates different environmental practices and actions such as tree plantation and environmental impact minimisation. For example, we derive a significant part of our manufacturing energy requirements from renewable energy resources including two wind farms generating a capacity of 1.25 MW each.

As a drug manufacturer, we are committed to ensuring our manufacturing facilities continuously work towards reducing impact on the environment. We have adhered to the provisions and rules of the Consolidated Consent and Authorization of Gujarat Pollution Control Board for the following environmental acts & rules:

• Water: Prevention and Control of Pollution
• Air: Prevention and Control of Pollution
• Hazardous Waste: Management, Handling & Trans-boundary Movement

Our Matoda formulation and API manufacturing site has been recommended for ISO 14001 and OHSAS 18001 certificate which is related to Environmental Aspects and Hazard Identification, Risk Assessment and Control

We contribute to society by supporting various NGO’s in selected programs, participating in medical camps, working with cancer patient associations and consistently reaching out beyond the boundaries of our company to touch communities in which we work. Some of our community initiatives are:

• Medical check-up camps in villages.
• Free medicines and medical camps in regions affected by natural disasters.
• School building extension/ renovation in villages.
• Employee volunteerism by conducting blood donation camps every year or raising funds to support cancer patient associations.
• Donations in institutions like Kanya Kelavni Mandal run by Chief Minister for Child Education.
• Scholarship scheme.
• Donations to communities with limited resources.
• Cancer patients and former cancer patients direct support and sponsorship.
• To provide communities with limited resources those products which are not accessible to them due to their high cost, such as biosimilar products.
• To run campaigns in India to cover short supply from other manufacturers for critical care products.

Accord assumes its business and ethical responsibility to create a safe and healthy workplace for its employees and a clean environment. We are committed to this corporate citizenship goal.

Accord favours cultural exchange and diversity and enforces at all levels, responsible business practices and upholds the highest ethical standards in everything from research and development to sales and marketing. In order to strengthen the commitment of our employees towards continual improvement in Environmental, Health and Safety (EHS), their contribution to this is considered a significant factor in their annual performance appraisal.

Accord is committed to putting user safety at the heart of our product offering and believes in enriching the lives of people by providing innovative high quality medicines. We characterise these as either Preventative or Protective measures designed to prevent occupational (pharmacy) exposure to cytotoxic residues.

Central to our Preventative measures is PharmaShield®: a system consisting of a superficial plastic sheathing around the vial, going from the reinforced non- PVC base to the vial seal specifically developed to minimize occupation exposure to potential toxic residues in cytotoxic vials.

Additionally, we ensure that before leaving our factories 100% of our cytotoxic products undergo an extensive validated washing cycle and visual inspection. In conjunction, and based on our pharmaceutical expertise and best practices, an innovative packaging design for our products is implemented to facilitate product identification and to minimize potential errors when dispensing a drug.